A study published in the University of Birmingham, published in Science Translational Medicine, found that drugs commonly used to treat obesity and type 2 diabetes can be used to lower brain pressure.
Elevation of intracranial pressure is a common emergency situation, such as increased hydrocranial pressure in both hydrocephalus and stroke, and increased intracranial pressure is also characteristic of idiopathic intracranial hypertension (IIH). IHH causes severe headache and increased pressure around the nerves inside the eye. It also causes 25% of untreated people to be permanently blind.
In a three-year period, researchers at the University of Birmingham examined whether GLP-1 receptor agonists (an existing drug used to treat diabetes and obesity) can be raised in animals with elevated brain pressure. Reduce intracranial pressure in the model.
The Alexandra Dr. Sinclair of the Institute of Metabolism and Systems at the University of Birmingham said that treatments that reduce brain stress are scarce, so new treatments are urgently needed.
The current major treatment for IIH is acetazolamide, which does not work in many patients and has serious side effects. Previous studies have shown that more than 48% of patients discontinue taking because of side effects. Stop taking the medicine.
We have shown that the GLP-1 receptor agonist Extendin-4 is able to rapidly and significantly reduce brain pressure, with approximately 44% of patients experiencing significant changes. More importantly, we found that the effect lasted for at least 24 hours.
These findings can be rapidly converted to new treatments for IIH because GLP-1 receptor agonists are very safe and widely used to treat diabetes and obesity. They may also have therapeutic effects on other diseases that increase intracranial pressure, such as stroke, hydrocephalus, and traumatic brain injury.
They may also have other conditions to increase brain pressure, including stroke changes, hydrocephalus and traumatic brain damage. (zhuliee 206757)